Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PDS Biotechnology Corporation (PDSB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.69-0.02 (-0.35%)
At close: 04:00PM EST
5.73 +0.04 (+0.70%)
After hours: 04:00PM EST
Advertisement

PDS Biotechnology Corporation

25B Vreeland Road
Florham Park, NJ 07932
United States
800 208 3343
https://www.pdsbiotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Dr. Frank K. Bedu-Addo Ph.D.Pres, CEO & Director675kN/A1964
Dr. Gregory L. ConnChief Scientific Officer384.79kN/A1955
Ms. Lauren V. Wood M.D.Chief Medical Officer416.38kN/A1960
Mr. Matthew C. Hill CPACFO & Principal Accounting OfficerN/AN/A1969
Dr. Joe J. DervanVP of R&DN/AN/AN/A
Ms. Deanne RandolphVP of Commercial Devel. & Head of Investor RelationsN/AN/AN/A
Ms. Hillary YegenVP of LegalN/AN/AN/A
Dr. Mark Baxter Ph.D.Sr. VP of Global QualityN/AN/AN/A
Ms. Janetta TrochimiukControllerN/AN/A1963
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Corporate Governance

PDS Biotechnology Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement